MediGene AG Participates At Four National And International Conferences In January 2017
Martinsried/Munich, 16 December 2016. Medigene AG (FSE: MDG1, Prime Standard) announces its participation at four upcoming scientific and investor conferences:
• Ringberg Conference 2017
Date: 03 January 2017
Location: Schloss Ringberg, Tegernsee, Germany
Dr. Markus Dangl, Senior Vice President Research & Pre-Clinical Development, will give a presentation on the topic: "TCRs and neoantigens: The perfect solution for personalized cancer immunotherapy?"
• Oddo Forum
Date: 05 - 06 January 2017
Location: Lyon, France
• J.P. Morgan Healthcare Conference
Date: 09 - 12 January 2017
Location: San Francisco, USA
• Phacilitate, Cell & Gene World 2017
Date: 17 - 20 January 2017
Location: Miami, USA
Medigene's Senior Vice President Medical Affairs & CMO, Dr. Kai Pinkernell, will present on 18 January 2017 a case study in the session: "Optimizing preclinical data packages for efficient cell & gene therapy clinical translation"
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
For more information, please visit www.medigene.com
• Ringberg Conference 2017
Date: 03 January 2017
Location: Schloss Ringberg, Tegernsee, Germany
Dr. Markus Dangl, Senior Vice President Research & Pre-Clinical Development, will give a presentation on the topic: "TCRs and neoantigens: The perfect solution for personalized cancer immunotherapy?"
• Oddo Forum
Date: 05 - 06 January 2017
Location: Lyon, France
• J.P. Morgan Healthcare Conference
Date: 09 - 12 January 2017
Location: San Francisco, USA
• Phacilitate, Cell & Gene World 2017
Date: 17 - 20 January 2017
Location: Miami, USA
Medigene's Senior Vice President Medical Affairs & CMO, Dr. Kai Pinkernell, will present on 18 January 2017 a case study in the session: "Optimizing preclinical data packages for efficient cell & gene therapy clinical translation"
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
For more information, please visit www.medigene.com